Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Last trade$0.36
Day change-$0.036 (-9.09%)
Day range$0.353 – $0.415
Volume3,978,750
Market cap$96M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$97.38M
Price / earnings
—
Price / book
-9.37×
Price / sales
-90.86×
EV / sales
-97.38×
EV / EBITDA
-2.73×
Profitability
Earnings per share
-$0.20
Return on assets
-182.66%
Return on equity
460.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.75×
Current ratio
0.81×
Quick ratio
0.63×
Cash ratio
0.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$56.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OTLK, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$8.7K
$127.44K
-$1.21M
—
$1.51M
$0
$0
$0
Cost of revenue
$16.97K
$149.33K
$29.63K
$0
$439.82K
$0
$0
$0
Gross profit
-$8.27K
-$21.89K
-$1.24M
—
$1.07M
$0
$0
$0
Selling, general and administrative
$7.55M
$9.5M
$8.61M
—
$9.68M
$7.98M
$11.95M
$10.35M
Research and development
$3.25M
$4.5M
$3.63M
—
$7.13M
$4.41M
$9.66M
$12.52M
Total operating expenses
$10.8M
$14.01M
$12.25M
—
$16.81M
$12.39M
$21.61M
$22.88M
Operating income
-$10.81M
-$14.03M
-$13.48M
—
-$15.75M
-$12.39M
-$21.61M
-$22.88M
Interest expense
$7
$0
$0
—
-$49.35K
$0
$48.88K
-$666.2K
Income before taxes
-$20.32M
-$4.45M
-$23.06M
—
-$20.15M
-$46.35M
$17.38M
$5.69M
Income taxes
$0
$0
$0
—
$0
$2.8K
$0
$0
Net income
-$20.32M
-$4.45M
-$23.06M
—
-$20.15M
-$46.36M
$17.38M
$5.69M
Net income attributable to common shareholders
-$20.32M
-$4.45M
-$23.06M
—
-$20.15M
-$46.36M
$17.38M
$5.69M
EBITDA
-$10.8M
-$14M
-$13.45M
$29.74K
-$15.72M
-$12.36M
-$21.58M
-$22.85M
Basic earnings per share
-$0.15
-$0.05
-$0.38
—
-$0.55
-$1.50
$0.72
$0.24
Diluted earnings per share
-$0.15
-$0.05
-$0.38
—
-$0.55
-$1.50
$0.72
$0.27
Recent news
Company coverage with links to the original publishers.
Outlook Therapeutics' LYTENAVA (bevacizumab gamma) received a Complete Response Letter from the FDA in December 2025, preventing approval for wet AMD treatment in the US. The drug is approved in Europe and positioned as a mid-priced alternative between compounded bevacizumab and premium anti-VEGF therapies, with potential expansion into branch retinal vein occlusion and diabetic macular edema indications.
Outlook Therapeutics announced FDA approval of LYTENAVA™ (bevacizumab-vikg), the first FDA-approved ophthalmic formulation of bevacizumab specifically designed for treating wet AMD. The approval provides 12 years of market exclusivity under BPCIA and positions the company to capture market share in the approximately $8.5 billion U.S. retina market. The company is launching commercial operations and expects to make LYTENAVA™ available to patients before year-end.
Outlook Therapeutics announced a $5.0 million registered direct offering of 8.5 million shares at $0.5855 per share to its largest stockholder GMS Ventures and Investments. The company also agreed to amend outstanding warrants held by GMS Ventures, reducing the exercise price from $1.78 to $0.5855 per share. Proceeds will be used for working capital and general corporate purposes.
Outlook Therapeutics (NASDAQ: OTLK) announced a best-efforts public offering of common stock and accompanying warrants to raise capital for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is subject to market conditions with no assurance of completion timing or terms.
U.S. stock futures rose on the first trading day of 2026, with the S&P 500 and Nasdaq 100 gaining in premarket trading. Key movers included Baidu jumping 12.2% on a spinoff announcement, Rubico surging 16.8% following an acquisition deal, while Outlook Therapeutics plummeted 56.5% after an FDA rejection and Intelligent Bio Solutions dropped 23.4% on a private placement announcement. Analysts predict modest 3-5% gains for 2026 after a record-breaking 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.